Teva’s Q1 2024: Generics Grow, AUSTEDO Surges in the U.S., and a Steady Path Forward
TEVA, the ticker TEVA, reported its first-quarter 2024 earnings alongside a reaffirmed revenue forecast for the full year. The disclosure centers on a GAAP loss per share of $0.12 and a Non-GAAP diluted EPS of $0.48, with Q1 2024 revenues of $3.8 billion and a local-currency lift of 5% versus Q1 2023. The company anchors the narrative on its Generics business and AUSTEDO growth, while also flagging pipeline momentum and regulatory milestones that could influence 2024-26 dynamics for itself and peers in the pharma space.
In the language of earnings disclosures, the TEVA press release supplies EPS figures and a revenue forecast for the year, but does not publish a standalone EPS consensus figure or a stated earnings surprise relative to an external consensus in the document itself. That leaves readers with a core set of disclosed numbers to anchor expectations and a few qualitative signals to infer whether the market should revisit its assumptions about the company’s trajectory.
Quarterly Highlights: The Generics Engine, AUSTEDO, and AJOVY
The quarter’s performance benefits from two engines: the Generics business and AUSTEDO. Generics growth across all regions rose 9% in local currency terms versus Q1 2023, while AUSTEDO rose 67% in the United States, supporting Teva’s effort to stabilize and diversify revenue streams beyond price competition on off-patent products.
Beyond those lines, AJOVY delivered $113 million in Q1 2024 revenues, up 18% year over year, signaling continued uptake in the migraine franchise alongside broader neurology assets.
Pipeline and Regulatory Footnotes
The company pointed to recent FDA approvals of SIMLANDI and SELARSDI, the biosimilars to Humira and Stelara respectively, as evidence of a constructive regulatory tailwind for the near-to-medium term. In addition, Teva announced positive Phase 3 efficacy results for an olanzapine long-acting injectable (TEV’749), with no reported post-injection delirium/sedation syndrome (PDSS) observed to date. These updates matter not only for the core business but also for how investors think about competitive dynamics in specialty and biosimilar spaces.
Cash Flow, Earnings, and the 2024 Outlook
On the earnings line, the results show a GAAP loss per share of $0.12 and a Non-GAAP diluted EPS of $0.48. Operating cash flow registered at $124 million, with free cash flow of $32 million, underscoring the ongoing emphasis on cash generation even as the company cycles through high-visibility investments and working-capital needs.
Teva reaffirmed its full-year 2024 financial outlook: revenues are forecast in a range of $15.7 billion to $16.3 billion, and Adjusted EBITDA is projected at $4.5 billion to $5.0 billion. The call for a steady, if modest, improvement in profitability sits atop a narrative focused on product diversity, pipeline progression, and geographic breadth.
What This Could Portend for Teva and Sector Peers
The quarter’s composition—robust performance from Generics, meaningful U.S. growth from AUSTEDO, and the cadence of new regulatory approvals—suggests Teva is leaning into a multi-pronged strategy: leverage non-branded growth to complement price-competitive generics, while pursuing specialty and biosimilar opportunities to diversify risk and extend product lifecycle value.
For peers in the pharmaceutical space, the signal is twofold. First, the combination of generic volume recovery and enhanced specialty monetization (like AUSTEDO and AJOVY) can sustain a broader earnings floor even when legacy commercial models face ongoing pressure. Second, regulatory catalysts (SIMLANDI, SELARSDI) show that biosimilars and complex specialty products can meaningfully contribute to topline growth, potentially rebalancing some of the near-term headwinds around payer dynamics and formulary access.
If Teva can convert pipeline progress and regulatory wins into durable revenue streams and margins, the company may increasingly resemble a diversified specialty-pharma proxy for investors watching the transition from pure generics exposure to a more balanced portfolio. Sector peers with similar exposure to biosimilars, complex therapeutics, and international growth could see these moves recalibrate their own risk-reward profiles, particularly in markets where price erosion on generics has been most acute.
Bottom Line: Stability with Optionality
Teva’s Q1 2024 print offers a mixed-but-manageable picture: solid top-line progress in local currency terms, a mid-single-digit Q1 revenue beat in broad terms, and a reaffirmed 2024 revenue and EBITDA outlook that maintains optionality for add-on upside from pipeline wins and new product approvals. The market will likely parse whether AUSTEDO’s momentum can be sustained through the year and whether biosimilar entries—coupled with the ongoing strength of Generics—can offset ongoing pricing pressure in the broader pharmaceutical ecosystem.
For investors tracking EPS, earnings surprises, and revenue forecasts, Teva provides a clean dataset: GAAP losses, non-GAAP earnings, and a transparent full-year forecast. The absence of an explicit EPS consensus in the release means the stock’s near-term reaction could hinge on external analyst commentary and how the company’s ongoing cash-generation profile translates into capital allocation decisions, such as dividends, buybacks, or strategic M&A in the evolving landscape of generics and specialty medicines.